Shandong Tefaman Pharmaceutical Co Ltd.

Primary objectives: 1. To evaluate the effect of TPN729MA tablets on the pharmacokinetic characteristics of alcohol; 2. To evaluate the effect of alcohol on the pharmacokinetic characteristics of TPN729MA tablets; 3. To evaluate the effect of co-administration of TPN729MA tablets and alcohol on blood pressure and pulse rate in healthy male participants. Secondary objectives: To evaluate the safety of co-administration of TPN729MA tablets and alcohol in healthy male participants.

Primary objectives: 1) To evaluate the effect of a single oral administration of TPN729MA tablets on the QT/QTc interval in healthy Chinese participants. Secondary objectives: 1) Changes in electrocardiographic parameters (HR, PR, QRS interval) before and after administration. 2) The number of participants with abnormal T wave morphology and U waves after administration. 3) The number of participants with arrhythmias after administration. 4) To evaluate the pharmacokinetic (PK) characteristics of TPN729MA tablets in healthy participants after administration. 5) To evaluate the safety and tolerability of TPN729MA tablets in healthy participants after administration.

Primary objective: To evaluate the acute effects of a single oral administration of TPN729MA tablets on semen quality (total motility, PR progressive motility, NP non-progressive motility, sperm concentration, sperm morphology staining, and volume) in healthy Chinese male participants; to investigate the exposure of TPN729MA in seminal plasma. Secondary objective: To observe the safety of a single oral administration of TPN729MA tablets in healthy male participants.